Published in Gene Therapy Weekly, January 27th, 2000
Over the next nine months AstraZeneca will evaluate a version of Vion's TAPET (Tumor Amplified Protein Expression Therapy) bacterial vector, armed with EPTTCO's prodrug activation technology, which uses enzymes to convert inactive prodrugs into cytotoxic anti-cancer agents.
Under the terms of the agreement, Vion and EPTTCO will co-develop these specific EPTTCO-armed TAPET vectors and test them in preclinical cancer models....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.